Suppression of N-Ras by shRNA-expressing plasmid increases sensitivity of HepG2 cells to vincristine-induced growth inhibition

Cancer Gene Therapy

Volumn 16, Issue 9, 2009, Pages 693-702

  Sun, H X ^a   He, H W ^a   Zhang, S H ^a   Liu, T G ^a   Ren, K H ^a   He, Q Y ^a   Shao, R G ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Cancer therapy; Hepatoma; N Ras; shRNA; Vincristine

Indexed keywords

GLYCOPROTEIN P; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN KINASE B; SHORT HAIRPIN RNA; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; ONCOGENE N RAS; PLASMID; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DOWN-REGULATION; FEMALE; GENE EXPRESSION; GENE THERAPY; GENES, RAS; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, NUDE; PLASMIDS; RNA INTERFERENCE; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 68949201699     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.14     Document Type: Article

References (43)

1. Garcia M, Jemal A, Ward EM, , Center MM, Hao Y, Siegel RL et al. Global Cancer Facts & Figures 2007. American Cancer Society: Atlanta, GA, 2007.
2. Yin JQ, Gao J, Shao R, Tian WN, Wang J, Wan Y. siRNA agents inhibit oncogene expression and attenuate human tumor cell growth. J Exp Ther Oncol 2003; 3: 194-204.
3. Arbuthnot P, Thompson LJ. Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma. Gastroenterology 2008; 14: 1670-1681.
4. Barbacid M. ras Genes. Annu Rev Biochem 1987; 56: 779-827.
5. Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: conserved structure and molecular mechanism. Nature 1991; 349: 117-127.
6. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
7. Campbell PM, Der CJ. Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol 2004; 14: 105-114.
8. Adjei AA. Blocking oncogenic ras signaling for cancer therapy. J Natl Cancer Inst 2001; 93: 1062-1074.
9. Vojtek AB, Der CJ. Increasing complexity of the Ras signaling pathway. J Biol Chem 1998; 273: 19925-19928.
10. Sorrentino R, Porcellini A, Spalletti-Cernia D, Lombari V, Vecchio G, Laccetti P. Inhibition of MAPK activity, cell proliferation, and anchorage-independent growth by N-Ras antisense in an N-ras-transformed human cell line. Antisense Nucleic Acid Drug Dev 2001; 11: 349-358.
11. Richards CA, Short SA, Thorgeirsson SS, Huber BE. Characterization of a transforming N-ras gene in the human hepatoma cell line Hep G2: additional evidence for the importance of c-myc and ras cooperation in hepatocarcinogenesis. Cancer Res 1990; 50: 1521-1527.
12. Stone AA, Chambers TC. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp Cell Res 2000; 254: 110-119.
13. VanderWeele DJ, Zhou R, Rudin CM. Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol Cancer Ther 2004; 3: 1605-1613.
14. Chen S, Guttridge DC, You Z, Zhang Z, Fribley A, Mayo MW et al. Wnt-1 signaling inhibits apoptosis by activating β-catenin/T cell factor-mediated transcription. J Cell Biol 2001; 152: 87-96.
15. Estlin EJ, Ronghe M, Burke GAA, Yule SM. The clinical and cellular pharmacology of vincristine, corticosteroids, l-asparaginase, anthracyclines and cyclophosphamide in relation to childhood acute lymphoblastic leukaemia. Br J Haematol 2000; 110: 780-790.
16. Rosenthal S, Kaufman S. Vincristine neurotoxicity. Ann Intern Med 1974; 80: 733-737.
17. Huang C, Li M, Chen C, Yao Q. Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets 2008; 12: 637-645.
18. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-553.
19. Li Z, Xiong F, Lin Q, d'Anjou M, Daugulis AJ, Yang DS et al. Low-temperature increases the yield of biologically active herring antifreeze protein in pichia pastoris. Protein Expr Purif 2001; 21: 438-445.
20. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194: 1861-1874.
21. Datta SR. Cellular survival: a play in three Akts. Genes Dev 1999; 13: 2905-2927.
22. Birkenkamp KU, Geugien M, Schepers H, Westra J, Lemmink HH, Vellenga E. Constitutive NF-kappa B DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia 2004; 18: 103-112.
23. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and Ikappa Balpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003; 101: 1053.
24. Eskandarpour M, Kiaii S, Zhu C, Castro J, Sakko AJ, Hansson J. Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. Int J Cancer 2005; 115: 65-73.
25. Ryo A, Suizu F, Yoshida Y, Perrem K, Liou YC, Wulf G et al. Regulation of NF-κB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell 2003; 12: 1413-1426.
26. Liu T, Yin JQ, Shang B, Min Z, He H, Jiang J et al. Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancer. Cancer Gene Ther 2004; 11: 748-756.
27. Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 385-392.
28. Amir G, Issakov J, Meller I, Sucher E, Peyser A, Cohen IJ et al. Expression of p53 gene product and cell proliferation marker Ki-67 in Ewing's sarcoma: Correlation with clinical outcome. Hum Pathol 2002; 33: 170-174.
29. Plattner R, Gupta S, Khosravi-Far R, Sato KY, Perucho M, Der CJ et al. Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells. Oncogene 1999; 18: 1807-1817.
30. Krasilnikov MA. Phosphatidylinositol-3 Kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation apoptosis (the progress of which is inhibited by PI3K). Biochemistry (Mosc) 2000; 65: 59-67.
31. Sarkar F, Li Y. NF-kappaB: a potential target for cancer chemoprevention and therapy. Front Biosci 2008; 13: 2950-2959.
32. Hu L, Shi Y, Hsu J, Gera J, Van Ness B, Lichtenstein A. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 2003; 101: 3126.
33. Emdad L, Sarkar D, Su ZZ, Randolph A, Boukerche H, Valerie K et al. Activation of the nuclear factor κB pathway by astrocyte elevated gene-1: implications for tumor progression and metastasis. Cancer Res 2006; 66: 1509-1516.
34. Kim HJ, Hawke N, Baldwin AS. NF-kappa B and IKK as therapeutic targets in cancer. Cell Death Differ 2006; 13: 738-747.
35. Armstrong MB, Bian X, Liu Y, Subramanian C, Ratanaproeksa AB, Shao F et al. Signaling from p53 to NF-kappaB determines the chemotherapy responsiveness of neuroblastoma. Neoplasia 2006; 8: 964-974.
36. Koong AC. Hypoxic activation of nuclear factor-kappa B is mediated by a Ras and Raf signaling pathway and does not involve MAP kinase (ERK1 or ERK2). Cancer Res 1994; 54: 5273-5279.
37. Huang Y, Fang Y, Wu J, Dziadyk JM, Zhu X, Sui M et al. Regulation of Vinca alkaloid-induced apoptosis by NF-κB/IkB pathway in human tumor cells. Mol Cancer Ther 2004; 3: 271-277.
38. Skobeleva N, Menon S, Weber L, Golemis EA, Khazak V. In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway-and microtubule-targeting inhibitors. Mol Cancer Ther 2007; 6: 898.
39. Zhai BJ, Shao ZY, Zhao CL, Hu K, Wu F. Development and characterization of multidrug resistant human hepatocarcinoma cell line in nude mice. World J Gastroenterol 2006; 12: 6614-6619.
40. Chen B, Jin F, Lu P, Lu XL, Wang PP, Liu YP et al. Effect of mitogen-activated protein kinase signal transduction pathway on multidrug resistance induced by vincristine in gastric cancer cell line MGC803. World J Gastroenterol 2004; 10: 795-799.
41. Garcia R, Franklin RA, McCubrey JA. EGF induces cell motility and multi-drug resistance gene expression in breast cancer cells. Cell Cycle 2006; 5: 2820-2826.
42. Schaich M, Illmer T. Mdr1 gene expression and mutations in Ras Proto-oncogenes in acute myeloid leukemia. Leuk Lymphoma 2002; 43: 1345-1354.
43. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992; 255: 459-462.